Clinical Trials Sponsored by Rigel Pharmaceuticals

Total 19965 results

University of Michigan Rogel Cancer Center

Completed

A Pilot Trial to Determine the Extent of Inter- and Intra-Treatment Organ Motion Using Active Breathing Control Device (ABC) in Patients With Pancreatic Cancer

Pancreatic Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer

Head and Neck Squamous Cell Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Chemoradiation and Tetrathiomolybdate (TM) in Patients With Esophageal Carcinoma

Esophageal Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia

Acute Myelogenous Leukemia

United States
University of Michigan Rogel Cancer Center

Completed

Imaging Biomarker for Early Detection of Treatment Efficacy During Breast Cancer Neoadjuvant Chemotherapy

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients (HUM21469)

Nausea | Vomiting | Terminally Ill

United States
University of Michigan Rogel Cancer Center

Terminated

A Study of Mitomycin C, Irinotecan, and Cetuximab

Colorectal Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE)

Cancer of Larynx

United States
University of Michigan Rogel Cancer Center

Terminated

Clinical Trial Of Neoadjuvant Chemotherapy (NAC)In Upper Tract Urothelial Carcinoma (UTUC)

Bladder Cancer | Urothelial Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Benefits of Exercise Training in Head and Neck Cancer Patients Undergoing Organ-Preserving Definitive Therapy

Head and Neck Squamous Cell Carcinoma

United States
University of Michigan Rogel Cancer Center

Completed

Docetaxel Plus Capecitabine in Newly Diagnosed Localized or Locally Advanced Prostate Cancer

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Early Assessment of Treatment Response Using Functional Diffusion Mapping

Prostate Cancer

United States
University of Michigan Rogel Cancer Center

Withdrawn

A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer

Cancer of Head and Neck

United States
University of Michigan Rogel Cancer Center

Completed

Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers

Nasopharyngeal Cancer | Fibrosarcoma | Wilms Tumor | Brain Tumor, Recurrent | Carcinoma, Round Cell

United States
University of Michigan Rogel Cancer Center

Completed

Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC

Extensive-Stage Small Cell Lung Cancer

United States
University of Michigan Rogel Cancer Center

Completed

A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer

Head and Neck Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

A Multi-Centered Trial Evaluating the Role of Vitamin D Metabolism in Non-Small Cell Lung Cancer (EBUS)

Non-Small Cell Lung Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Low-Intensity Preparation and Allogeneic Transplant in Patients With Cancers of the Blood

Myelodysplastic Syndromes | Myeloproliferative Disorders | Lymphoma, Malignant | Waldenstrom's Macroglobulinemia | Myeloma, Plasma-Cell

United States
University of Michigan Rogel Cancer Center

Completed

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Multiple Myeloma

United States
University of Michigan Rogel Cancer Center

Completed

Evaluation of Tumor Factors in Breast Cancer Treated With Docetaxel and Capecitabine

Breast Cancer

United States
University of Michigan Rogel Cancer Center

Completed

Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States
University of Michigan Rogel Cancer Center

Completed

Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma

Esophageal Cancer

United States
University of Michigan Rogel Cancer Center

Terminated

Lapatinib (GW572016) for Metastatic or Recurrent Squamous Cell Carcinoma Esophagus

Metastatic or Recurrent Squamous Cell Carcinoma of the Esophagus

United States
University of Michigan Rogel Cancer Center

Terminated

Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin's

United States
University of Michigan Rogel Cancer Center

Terminated

Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood

Myelodysplastic Syndromes | Leukemia | Multiple Myeloma | Lymphoma, Low-Grade | Lymphoma, Non-Hodgkin's

United States
Corbus Pharmaceuticals Inc.
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Recruiting

A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors

Solid Tumor, Adult

United States, Spain, Turkey, United Kingdom
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
Ahn-Gook Pharmaceuticals Co.,Ltd
Daehwa Pharmaceutical Co., Ltd.

Not yet recruiting

Phase III Study to Evaluate the Efficacy and Safety of AGSAVI in Patients With Essential Hypertension Inadequately Controlled With AGLS

Essential Hypertension
ChemGenex Pharmaceuticals

Terminated

Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)

Myeloid Leukemia, Chronic, Chronic-Phase | Myeloid Leukemia, Chronic | Myeloid Leukemia, Chronic, Accelerated-Phase | Blast Phase

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Terminated

Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

Follicular Lymphoma

Italy, Israel, Germany, France, Greece, Spain, Switzerland
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

France, United States, Spain, Korea, Republic of, Australia, Israel, India, Thailand, China, Czech Republic, Belgium, New Zealand, Russian Federation, Finland, South Africa, United Kingdom, Italy, Brazil, Hungary, Puerto Rico, A... and more
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

Amyloidosis

United States
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Intra-Abdominal Infections

Bacterial Infections and Mycoses | Cholecystitis | Appendicitis | Peritonitis | Pancreatitis
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Hospital-Acquired Pneumonia

Pneumonia
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

Tumors | Non-Hodgkins's Lymphoma

United States
University of Michigan Rogel Cancer Center
Genzyme, a Sanofi Company; Otsuka Pharmaceutical Development & Commercialization...

Completed

Multi-center Study of Myeloablative Allo Stem Cell Transplant for Non-remission AML Using CloBu4 Regimen (CloBu4)

Acute Myeloblastic Leukemia

United States, Canada
Jina Pharmaceuticals Inc.
Novum Pharmaceutical Research Services; Lambda Therapeutic Research Ltd.; Intas...

Recruiting

Evaluate Efficacy and Safety of Endoxifen in Bipolar I Disorder Patients

Bipolar I Disorder

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Belgium
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients (EVOLUTION)

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

Multiple Myeloma

Austria
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

Multiple Myeloma

Belgium, France, Germany
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Complicated Lower Urinary Tract Infection or Pyelonephritis

Urinary Tract Infections | Pyelonephritis
Johnson & Johnson Pharmaceutical Research & Development...
ALZA; Sequus Pharmaceuticals

Terminated

CAELYX Versus Paclitaxel HCl in Patients With Epithelial Ovarian Carcinoma Following Failure of First-Line, Platinum-Based Chemotherapy

Ovarian Neoplasms
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

Multiple Myeloma

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

Non-Small Cell Lung Cancer

Belgium
ChemGenex Pharmaceuticals

Completed

Pharmacokinetic (PK) Study of Homoharringtonine (Omacetaxine Mepesuccinate) Administered Subcutaneously to Patients With Advanced Solid and Hematologic Tumors

Hematologic Tumors

United States
Millennium Pharmaceuticals, Inc.
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

Multiple Myeloma | Non-Hodgkin's Lymphoma

Israel, Italy, Poland, South Africa, United Kingdom
Johnson & Johnson Pharmaceutical Research & Development...
Peninsula Pharmaceuticals, Inc.

Completed

Doripenem in the Treatment of Ventilator-Associated Pneumonia

Pneumonia | Ventilators, Mechanical

Clinical Trials Sponsored by Rigel Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations